Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanism of BCDX2-mediated RAD51 nucleation on short ssDNA stretches and fork DNA. | Nucleic Acids Res | 2024 | 39268578 | PubTator, text mining | PubMed |
| Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data. | Eur J Med Genet | 2024 | 39260602 | PubTator, text mining | PubMed |
| Prevalence of germline variants in Brazilian pancreatic carcinoma patients. | Sci Rep | 2024 | 39256447 | PubTator, text mining | PubMed |
| Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families. | J Pers Med | 2024 | 39202057 | PubTator, text mining | PubMed |
| Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing. | Curr Issues Mol Biol | 2024 | 39194688 | PubTator, text mining | PubMed |
| The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory. | Cancer Genomics Proteomics | 2024 | 39191493 | PubTator, text mining | PubMed |
| A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer. | Cancer Med | 2024 | 39149814 | PubTator, text mining | PubMed |
| Strategies for the prevention or reversal of PARP inhibitor resistance. | Expert Rev Anticancer Ther | 2024 | 39145413 | PubTator, text mining | PubMed |
| Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy. | Gastric Cancer | 2024 | 39110344 | PubTator, text mining | PubMed |
| Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial. | BMJ Open | 2024 | 39107016 | PubTator, text mining | PubMed |
| Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene. | Genet Med | 2024 | 39096152 | PubTator, text mining | PubMed |
| Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution. | J Obstet Gynaecol Res | 2024 | 39077936 | PubTator, text mining | PubMed |
| High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers. | NAR Cancer | 2024 | 39055334 | PubTator, text mining | PubMed |
| Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes. | Cancers (Basel) | 2024 | 39001430 | PubTator, text mining | PubMed |
| Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. | Ann Oncol | 2024 | 38986768 | PubTator, text mining | PubMed |
| Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis. | Front Oncol | 2024 | 38978731 | PubTator, text mining | PubMed |
| Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes. | Ann Surg Oncol | 2024 | 38976158 | PubTator, text mining | PubMed |
| Molecular alterations and prognosis of breast cancer with cutaneous metastasis. | Diagn Pathol | 2024 | 38970069 | PubTator, text mining | PubMed |
| Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report. | Front Pharmacol | 2024 | 38953104 | PubTator, text mining | PubMed |
| Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. | Cancer Med | 2024 | 38898688 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=10